MedCity News
Trial results add to uses for Exact Sciences test
The genomic test, known as Oncotype DX, can help predict whether women with certain forms of breast cancer will benefit from chemotherapy and those who won t. The latest trial results extend the test s reach.
Shares1
A clinical trial shows that a genomic test from diagnostics company Exact Sciences can help more women with early-stage breast cancer avoid chemotherapy.
The test, Oncotype DX, had already demonstrated its ability to predict whether chemotherapy would benefit women with breast cancer that has not spread to lymph nodes, known as node-negative breast cancer.